Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram and nortriptyline versus placebo with standard psychological care for depression in Parkinson's disease
2018-002942-35Phase 3Unknown
- Sponsor
- University College London Comprehensive Clinical Trials Unit
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in depression in Parkinson's disease and major depressive disorder (MDD) comparing Escitalopram + standard psychological care, Nortriptyline + standard psychological care and Placebo + standard psychological care (3 arms). Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
escitalopramnortriptyline
03
Conditions
depression in Parkinson's diseasemajor depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-002942-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002942-35.